{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:31:40Z","timestamp":1772915500512,"version":"3.50.1"},"reference-count":8,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,4,12]],"date-time":"2006-04-12T00:00:00Z","timestamp":1144800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Backround\u2002<\/jats:bold> Peroxisomal proliferator\u2010activated receptors (PPAR)\u2010 \u03b3 are expressed abundantly in ACTH\u2010secreting pituitary tumours. The PPAR\u2010gamma activator rosiglitazone has been shown to suppress ACTH secretion in human adrenocorticotroph tumour cells <jats:italic>in vitro<\/jats:italic>, and prevent and reduce adrenocorticotroph tumour development in mouse models <jats:italic>in vivo<\/jats:italic>.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To evaluate the effect of rosiglitazone in patients with persistently elevated plasma ACTH levels postbilateral adrenalectomy for Cushing's disease.<\/jats:p><jats:p><jats:bold>Patients\u2002<\/jats:bold> Seven patients were treated with rosiglitazone 8\u00a0mg orally per day for 12\u00a0weeks.<\/jats:p><jats:p><jats:bold>Measurements\u2002<\/jats:bold> Plasma ACTH was measured at two hourly intervals from 09:00\u00a0h to 17:00\u00a0h before and after 6 and 12\u00a0weeks of treatment.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Plasma ACTH at 09:00\u00a0hours immediately before the usual morning hydrocortisone dose was 2599\u00b70\u00a0\u00b1\u00a0899\u00b77\u00a0ng\/l (mean \u00b1 SEM) basally and 1547\u00b76\u00a0\u00b1\u00a0515\u00b77\u00a0ng\/l after 12\u00a0weeks of rosiglitazone, whereas levels at 17:00\u00a0h were 1433\u00b74\u00a0\u00b1\u00a0506\u00b72\u00a0ng\/l (mean \u00b1 SEM) basally and 1122\u00b73\u00a0\u00b1\u00a0460\u00b79\u00a0ng\/l at 12\u00a0weeks (all nonsignificant).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> This study showed no effect of rosiglitazone treatment at maximum approved doses in lowering plasma ACTH levels in patients post bilateral adrenalectomy for Cushing's disease.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2006.02501.x","type":"journal-article","created":{"date-parts":[[2006,4,21]],"date-time":"2006-04-21T10:31:51Z","timestamp":1145615511000},"page":"519-522","source":"Crossref","is-referenced-by-count":34,"title":["The PPAR\u2010gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome"],"prefix":"10.1111","volume":"64","author":[{"given":"Karen R.","family":"Mullan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"McCance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Brew","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,12]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb02371.x"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.1.165"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm784"},{"key":"e_1_2_4_5_2","unstructured":"Munir A. Song F. Ince P. Ross R. Newell\u2010Price J.A pilot study of prolonged high\u2010dose rosiglitazone therapy (12 mg\/day) in Nelson's syndrome. Abstract OC 24 195th Meeting of the Society for Endocrinology joint with Diabetes UK and the Growth factor Group Royal College of Physicians London UK."},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02193.x"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1746"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510173"},{"key":"e_1_2_4_9_2","unstructured":"Heaney A.P.(2003) Functional PPAR\u2010gamma receptor is a novel therapeutic target for ACTH\u2010secreting pituitary adenomas (Cushing's disease). Conference Proceeding 85th Annual Meeting 2003 The Endocrine Society Philadelphia PA USA June 19\u201322 2003 OR7\u20104."}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2006.02501.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2006.02501.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T19:22:59Z","timestamp":1697224979000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2006.02501.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,12]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1111\/j.1365-2265.2006.02501.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02501.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,12]]}}}